Vispacabtagene regedleucel

Cell therapy

Also known as CB-010

DiscontinuedCD19
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-10-06), for financing reasons

Caribou's board approved a restructuring that discontinues the clinical trials and further development of vispa-cel and CB-011, citing the financing environment for allogeneic CAR-T. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Other / comorbidity
NCT06752876 · Caribou Biosciences, Inc.
2027-12 – 2029-04 · Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Nephritis
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 17 of them ahead of this one.

This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vispacabtagene Regedleucel: this drugDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SurovatamigPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4512Phase 1/2Antibody–drug conjugateCD22not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
JNJ-88998377Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
REGN5837Phase 1Multispecific antibodyCD22 x CD28not yet gradedNo reviewed efficacy summary in this indication
SHR-3079Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.